Ticker brief
ASND
last close
·
1 day
·
14 days
·
mkt cap
·
signals 14d
6
authors 14d
4
crowd 14d
+1.1σ
No price history on file for this name (likely non-equity or unlisted) — the “since then” column below stays blank.
Sentiment — last 14 days
daily mean sentiment, 2026-08-17 → 2026-08-25 · now +0.10 (−1 bearish … +1 bullish)
Who spoke4
| author | grade | trader score | signals | mean sent |
|---|---|---|---|---|
| @ResearchPulse1 | B | +1.48 | 3 | +0.42 |
| @BiopharmIQ | B | · | 1 | +0.15 |
| @FXCMOfficial | C | -0.01 | 1 | +0.00 |
| @OzmosiHealth | C | · | 1 | +0.10 |
Recent signals6of 6 in 14d — receipts included
| date (PT) | author | sent | what they said | since then | receipt |
|---|---|---|---|---|---|
| 2026-08-25 | @OzmosiHealth | +0.10 | Ascendis announced a Week 104 pivotal-trial data presentation at ISDS 2026. | · | tweet ↗ |
| 2026-08-20 | @ResearchPulse1 | +0.35 | Speculates ASND technology may underpin a new NVO monthly-dosing trial, contingent on pharmacokinetic data. | · | tweet ↗ |
| 2026-08-19 | @FXCMOfficial | +0.00 | Weekly hot-stock watchlist cites combined ratings, technicals and sentiment. | · | tweet ↗ |
| 2026-08-18 | @BiopharmIQ | +0.15 | Biotech news roundup lists trial, regulatory, acquisition and access catalysts with opening moves. | · | tweet ↗ |
| 2026-08-17 | @ResearchPulse1 | +0.50 | Reports NVO chose ASND over Nanexa following preclinical platform validation. | · | tweet ↗ |
| 2026-08-17 | @ResearchPulse1 | +0.40 | Infers a monthly semaglutide Phase 1 program involving NVO and ASND, with competitive implications for VKTX. | · | tweet ↗ |
“Since then” = price move from the close on the signal's date (PT) to the latest close — what happened after they said it, not a backtest. A — means no trading session has closed since the signal yet. Sentiment is our extracted per-tweet score, −1…+1.